Michael J. Rosenberg

Counsel

Tel Aviv
michael.rosenberg@lw.com
+1.212.906.1829

PRACTICES

  • Capital Markets
  • Israel Practice
  • Mergers & Acquisitions
  • Public Company Representation

INDUSTRIES

  • Healthcare & Life Sciences
  • Technology

BAR QUALIFICATIONS

  • Israel (Registered Foreign Lawyer)
  • New York

EDUCATION

  • JD, Fordham University School of Law,
  • BA, Yeshiva University,
    magna cum laude

PROFILE

Michael Rosenberg advises companies, investment banks, and venture capital firms on complex corporate transactions and financings, with a focus on growth industries.

Drawing on his broad transactional experience and sector-specific knowledge, Michael helps clients successfully navigate a range of capital finance and M&A transactions, joint ventures, and late-stage venture capital financings. He brings particular experience in a number of growth industries, including healthcare, life sciences, fintech, and technology.

A significant focus of Michael’s work is public and private offerings of equity and debt. He represents both foreign and domestic issuers in initial public offerings (IPOs), secondary offerings, confidentially marketed public offerings (CMPOs), at-the-market (ATM) financings, 144A offerings, registered direct offerings, and private investments in public equity (PIPEs), as well as seed financings and later-stage venture capital financings.

Michael also represents companies in domestic and cross-border M&A transactions.

In addition to his transactional work, Michael advises corporate clients on securities law and corporate governance matters, and US Securities and Exchange Commission compliance.

Michael previously served as a member of the Fordham Moot Court and as an editor of the Fordham Journal of Corporate and Financial Law.

EXPERIENCE

Michael’s experience includes advising:

Capital Markets

  • MediWound Ltd, an Israeli based biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio therapeutic, non-surgical solutions for tissue repair and regeneration, in its US$30 million registered offering and concurrent private placement
  • MediWound Ltd, an Israeli based biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio therapeutic, non-surgical solutions for tissue repair and regeneration, in its US$15 million registered offering
  • The underwriters in connection with a convertible bond offering by Camtek
  • SpringWorks Therapeutics in its US$186.3 million initial public offering and US$287.5 million follow-on offering*
  • Scholar Rock Holding Corporation in its US$51 million and US$230 million public follow-on offerings*
  • Research Alliance Corporation in its US$137 million initial public offering and concurrent private placement*
  • Calliditas Therapeutics in its US$90 million initial public offering*
  • Pliant Therapeutics in its US$165 million initial public offering*
  • Kaleido Biosciences in its US$75 million initial public offering*
  • Advaxis in its US$20 million shelf offering*
  • Allena Pharmaceuticals in its US$20 million registered direct offerings*
  • Vascular Biogenics in its US$18 million registered direct offerings*
  • The underwriters in connection with Immunome’s US$35 million initial public offering*
  • The underwriters in connection with a follow-on offering for IntriCon Corporation*
  • Zealand Pharma in its US$89 million initial public offering*
  • Edge Therapeutics in its US$115 million initial public offering*
  • Iconix Brand Group in its offering of High Yield Convertible Notes*
  • Griffon Corporation in its 144A offering of high yield debt securities*
  • US Shale Solutions in its 144A offering in senior secured notes*
  • The underwriters in connection with a follow-on offering for BioLineRx*
  • Forward Pharma in its US$221 million initial public offering*

Venture Capital

  • SpringWorks Therapeutics in its US$125 million Series B financing to advance two late-stage rare disease oncology programs toward potential regulatory approval*
  • Navitor Pharmaceuticals in its Series D and Series C financings and issuance of convertible notes*
  • Imara Pharma in its US$63 million Series B financing*

Mergers & Acquisitions

  • ironSource, a software company that focuses on app monetization and distribution, on its US$4.4 billion all stock merger with Unity Software
  • HUB Cyber Security on its US$1.28 billion business combination with Mount Rainier Acquisition Corp.
  • Alpha Tau Medical, an Israel-based the developer of the alpha-radiation cancer therapy Alpha DaRT™, on its US$1 billion business combination with Healthcare Capital Corp., a special purpose acquisition company
  • Itamar Medical, an Israeli based medical device and digital health company in its US$538 million sale to ZOLL Medical
  • ironSource, a software company that focuses on app monetization and distribution, on its US$11 billion business combination with Thoma Bravo Advantage, a special purpose acquisition company
  • Alpha Healthcare Acquisition Corp.’s business combination with Humacyte*
  • Zealand Pharma’s US$205 million sale of certain royalty rights to Royalty Pharma*
  • AM-Pharma’s sale of a minority interest in the company to Pfizer and related option payment*
  • Dava Pharmaceuticals in its sale to Endo Pharmaceuticals*

*Matter handed prior to joining Latham